Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo

To see complete record on, please visit this link

Id: NCT01130909

Organisation Name: AstraZeneca

Overal Status: Terminated

Start Date: May 2010

Last Update: October 13, 2014

Lead Sponsor: AstraZeneca

Brief Summary: This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.

  • Healthy

Total execution time in seconds: 0.20563983917236